Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients
Bellerophon Therapeutics, Inc. (BLPH)
Last bellerophon therapeutics, inc. earnings: 4/6 10:23 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.bellerophon.com
Company Research
Source: GlobeNewswire
Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease Data to be Presented in a Poster Session at the 13th Annual Pulmonary Vascular Research Institute World Congress on Pulmonary Vascular Disease WARREN, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse® Phase 2b clinical trial (iNO-PF) for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) that supports actigraphy as a clinically meaningful endpoint will be the subject of a poster presentation at the 13th Annual Pulmonary Vascular Research Institute World Congress on Pulmonary Vascular Disease, which will take place January 31 through February 3, 2019,
Show less
Read more
Impact Snapshot
Event Time:
BLPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLPH alerts
High impacting Bellerophon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BLPH
News
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat